CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway

Background: Drug resistance is one of the biggest challenges in cancer therapy. temozolomide (TMZ) represents the most important chemotherapeutic option for glioma treatment. However, the therapeutic efficacy of TMZ remains very limited due to its frequent resistance in glioma, and the underlying me...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, Xin, Qu, Xuan, Guo, Kai, Meng, Xiangliang, Yang, Xing, Huang, Qike, Dou, Wenjie, Feng, Lin, Wei, Xinxin, Gao, Jiwei, Sun, Wei, Chao, Min, Han, Liying, Hu, Yaqin, Shen, Liangliang, Zhang, Jian, Wang, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375226/
https://www.ncbi.nlm.nih.gov/pubmed/34421346
http://dx.doi.org/10.7150/ijbs.60894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375226/
https://www.ncbi.nlm.nih.gov/pubmed/34421346
http://dx.doi.org/10.7150/ijbs.60894

Ejemplares similares